DDrare: Database of Drug Development for Rare Diseases

195. ヌーナン症候群
［臨床試験数：14，薬物数：15（DrugBank：5），標的遺伝子数：2，標的パスウェイ数：9］

Searched query = "Noonan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Glucose; Growth hormone; LOVASTATIN; Lamotrigin; Lamotrigin beta; Lovastatin; MAXOMAT ®, biosynthetic growth hormone; MEK162; Norditropin 24 IU; Norditropin SimpleXx; Other: Oral Glucose tolerance test; RhIGF-1/rhIGFBP-3; RhIGFBP-3; Simvastatin; Somatropin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00351221 (ClinicalTrials.gov)	May 2006	11/7/2006	Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome	A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome	Noonan Syndrome	Drug: rhIGF-1/rhIGFBP-3	Insmed Incorporated	NULL	Terminated	2 Years	16 Years	Both	24	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00351221
(ClinicalTrials.gov)

May 2006

11/7/2006

Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome

A Phase 2, Open-Label, Multicenter, Clinical Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 in Children With Growth Failure Due to Noonan Syndrome

Noonan Syndrome

Drug: rhIGF-1/rhIGFBP-3

Insmed Incorporated

NULL

Terminated

2 Years

16 Years

Both

Phase 2

United States